Veru Inc. Common Stock (VERU)
Stock · NASDAQ · Health Care
$2.31as of 10/16/2026
Price chart
Active signals
VERU Signal Track Record
How signals performed across all stocks →What VERU's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -6.8% | 39% | October 6, 2026 |
| Bollinger Band Breakdown | 21 | -1.9% | 43% | September 9, 2026 |
| Bollinger Band Breakout | 21 | -15.4% | 19% | August 10, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -11.4% | 17% | September 24, 2026 |
| Any 20-session window (baseline) | -4.2% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective andro…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 20
- Website
- verupharma.com/
Fundamentals
- 1-day range
- $2.28$2.48
- Market cap
- $37.08M
- P/E (trailing)
- —
- P/E (forward)
- -2.30
- EPS (trailing)
- $-0.59
- Dividend yield
- —
- Beta
- -1.21
- Avg. volume
- 238.8K
- Ex-dividend date
- April 28, 2014
- Dividend pay date
- May 7, 2014
How Veru Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Dec 16, 2024 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Veru Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VERUVeru Inc. Common Stock$2.3▼ 5.74%Market cap $37.08MP/E —$2.05$7.33
- IXHLIncannex Healthcare Inc. Common Stock$2.82▼ 2.08%Market cap $37.21MP/E —$2.49$14.91
- CRVOCervoMed Inc. Common Stock$2.24▼ 0.44%Market cap $37.33MP/E —$2.13$10
- APLMApollomics Inc. Class A Ordinary Shares$21.1▲ 0.48%Market cap $37.33MP/E —$10.01$42.12
- BYSIBeyondSpring Inc. Ordinary Shares$0.559▼ 3.95%Market cap $35.77MP/E —$0.5657$2.44
- NNVCNanoViricides Inc. Common Stock$1.38▲ 0.73%Market cap $35.56MP/E —$0.85$2.23
- LTRNLantern Pharma Inc. Common Stock$0.668▲ 0.15%Market cap $35.47MP/E —$0.651$4.58
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VERU Veru Inc. Common Stock | $37.08M | — | $2.3 | ▼ 5.74% | $2.05$7.33 |
| IXHL Incannex Healthcare Inc. Common Stock | $37.21M | — | $2.82 | ▼ 2.08% | $2.49$14.91 |
| CRVO CervoMed Inc. Common Stock | $37.33M | — | $2.24 | ▼ 0.44% | $2.13$10 |
| APLM Apollomics Inc. Class A Ordinary Shares | $37.33M | — | $21.1 | ▲ 0.48% | $10.01$42.12 |
| BYSI BeyondSpring Inc. Ordinary Shares | $35.77M | — | $0.559 | ▼ 3.95% | $0.5657$2.44 |
| NNVC NanoViricides Inc. Common Stock | $35.56M | — | $1.38 | ▲ 0.73% | $0.85$2.23 |
| LTRN Lantern Pharma Inc. Common Stock | $35.47M | — | $0.668 | ▲ 0.15% | $0.651$4.58 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- BARNETTE K GARY · August 13, 2026 · Buy1.8K @ $2.69
- Katzovitz Loren Mark · May 4, 2026 · Grant102.0K
- Hyun Grace · May 4, 2026 · Grant97.0K
- Harry Fisch · May 4, 2026 · Grant160.0K
- BARNETTE K GARY · May 4, 2026 · Grant160.0K
- STEINER MITCHELL SHUSTER · May 4, 2026 · Grant604.0K
- Lucy Lu · May 4, 2026 · Grant104.0K
- Michael L. Rankowitz · May 4, 2026 · Grant100.0K
- Greco Michele · May 4, 2026 · Grant164.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 3.40M
- Total value held
- $7.06M
- Institutional holders
- 54
- Unknown1.00M
- Unknown539.4K
- Unknown196.3K
- Unknown189.7K
- Unknown184.6K
- Unknown151.8K
- Unknown150.4K
- Unknown133.5K
- Unknown114.2K
- Unknown81.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
WestPark Capital initiates Veru coverage with $28 target
WestPark Capital has started tracking Veru Inc. with a positive outlook and set a price target of $28. This new analyst coverage places the firm's estimate above the current average analyst target of $24.50. The stock is currently trading near its 52-week low, making this fresh initiation a notable data point for investors watching the ticker.
WestPark Capital initiates Veru coverage with $28 target. WestPark Capital has started tracking Veru Inc. with a positive outlook and set a price target of $28. This new analyst coverage places the firm's estimate above the current average analyst target of $24.50. The stock is currently trading near its 52-week low, making this fresh initiation a notable data point for investors watching the ticker.